Cambridge Temperature Concepts Announces New CEO Claire Hooper
News Dec 23, 2013
Cambridge Temperature Concepts (CTC) has announced the appointment of Dr. Claire Hooper as Chief Executive Officer and a member of the Board of Directors, effective 9 December 2013.
Dr. Hooper brings global technology experience to this innovative telemedicine company and has a strong track record in developing and commercializing cutting-edge technologies internationally through partnership and M&A deals.
She brings more than 20 years of relevant industry experience, having previously served as technology director in PerkinElmer and Cambridge Imaging.
Sherry Coutu CBE, CTC’s Co-Chair, investor and serial entrepreneur, welcomes Dr. Hooper’s experience and leadership. She says: “In her new role as chief executive Claire will be responsible for delivering against an ambitious 2014 plan which focuses on rolling out our DuoFertility products in the US and developing the CTC platform within other related healthcare areas. Her results-oriented approach and ability to think strategically will provide the leadership and experience to help us grow.”
DuoFertility accurately predicts ovulation, optimizing a woman’s chances of successful conception. This proven application of telemedicine, based on the latest advances in wireless sensing technology, has created a platform that can be used to deliver other types of remote monitoring.
With Dr Hooper’s appointment, CTC Founder Dr. Shamus Husheer will take the role of Chief Technology Officer. Dr. Husheer says, “We are delighted that Dr. Hooper has agreed to take the commercial lead. She has the experience to drive the business forward and exploit effectively the significant market opportunities that lie ahead.”
Dr. Hooper says that telemedicine is a major opportunity: “CTC founders have put the company at the forefront of this expanding market. I am excited at the prospect of building on this and fully exploiting the opportunities in telemedicine, big data and digital health.”
Life sciences entrepreneur and investor, Dr. Andy Richards, Co-Chair at CTC, says that prior to appointment Claire had been an adviser and played an impressive role in leading and working with the CTC team.
“Claire has considerable experience of scaling healthtech operations. One of her objectives will be to commercialize the CTC platform and expand its use into other important medical areas where m-Health can make a real difference to patients.”
Dr. Hooper has a PhD in biochemistry and also serves as a non-executive director on the board of Abcodia Limited.
PhoreMost and Plexxikon Collaborate to Identify Novel Drug TargetsNews
PhoreMost, the UK-based biopharmaceutical company dedicated to drugging ‘undruggable’ disease targets, today announced it has signed a collaborative agreement with Plexxikon Inc., the small molecule structure-guided R&D centre of Daiichi Sankyo.READ MORE
‘Coffee Filter’ Makes Production of Cancer Drug Much CheaperNews
Making drugs cheaper doesn't always require pricey investments. What started out as a Bachelor project at TU/e laid the foundation for a much cheaper production of the promising cancer drug Z-endoxifen.READ MORE
Worms Exhibit Fear and Respond to Anti-anxiety MedsNews
A team of investigators has uncovered new clues about the mechanisms of fear and anxiety through an unlikely creature: the tiny nematode worm.READ MORE
Comments | 0 ADD COMMENT
World Congress on Advanced Biomaterials and Tissue Engineering
Jun 20 - Jun 21, 2018